compound 3a [Pipionne et al, 2018]   Click here for help

GtoPdb Ligand ID: 9965

Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: Compound 3a was identified and optimised in a hit-to-lead study to identify inhibitors of the non-canonical NF-κB cascade in tumour cells [1]. 3a inhibits activity of the NF-κB-inducing kinase, NIK (MAP3K14), and is a representative example of a series of compounds with NIK selectivity, the most potent of which was 3e (biochemical IC50 2.9 μM).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 60.91
Molecular weight 283.03
XLogP 3.75
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES Cc1nn(c(c1c1ccc(c(c1)Cl)Cl)N)C(=O)C
Isomeric SMILES Cc1nn(c(c1c1ccc(c(c1)Cl)Cl)N)C(=O)C
InChI InChI=1S/C12H11Cl2N3O/c1-6-11(12(15)17(16-6)7(2)18)8-3-4-9(13)10(14)5-8/h3-5H,15H2,1-2H3
Immunopharmacology Comments
This ligand is included in GToImmuPdb as it inhibits the non-canonical NF-κB signalling pathway, which is essential for immune responses, as well as being a driver of malignancy- see NIK SMI1 which is another NIK inhbitor, that has shown efficacy in a mouse model of the autoimmune disease systemic lupus erythematosus (SLE).